[1] Cui F, Shen L, Li L,et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis, 2017,23(5):765-772. [2] Li H, Yan L, Shi Y,et al. Hepatitis B virus infection: overview. Adv Exp Med Biol, 2020,1179(1):1-16.. [3] Ligat G, Schuster C, Baumert TF. Hepatitis Bvirus core variants, liver fibrosis, and hepatocellular carcinoma. Hepatology, 2019,69(1):5-8. [4] Kanda T, Goto T, Hirotsu Y,et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: A review. Int J Mol Sci, 2019,20(6):1358. [5] Sun J, Guo H, Yu X,et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure. BMC Gastroenterol, 2021,21(1):422. [6] Qi X. Peripheral blood lymphocyte-to-monocyte ratio predicts mortality in patients withHBV-related decompensated cirrhosis. Clin Lab, 2019,65(1):213-221. [7] Huang H, Liu Q, Zhu L,et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep, 2019,9(1):3284. [8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32. [9] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [10] 国家卫生健康委员会.中国卫生健康统计年鉴2019.中国协和医科大学出版社,2019:14-17. [11] 张茜,胡鹏. 慢性乙型肝炎治愈新药研究进展. 实用肝脏病杂志,2019,22(3):313-317. [12] Tsai KN, Kuo CF, Ou JJ. Mechanisms ofhepatitis B virus persistence. Trends Microbiol, 2018,26(1):33-42. [13] Jeng WJ, Liaw YF. Finite antiviral therapy in chronic hepatitisB patients with cirrhosis. Semin Liver Dis, 2021,41(3):349-357. [14] Li TY, Yang Y, Zhou G,et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol, 2019,25(27):3527-3537. [15] Zhao B, Sheng QJ, Qin Y,et al. Correlations of Helicobacter pylori with liver function, inflammatory factors and serum levels of FoxP3 and RORγt in patients with hepatitis B cirrhosis. Eur Rev Med Pharmacol Sci, 2021,25(1):459-465. [16] 李小清,汤成,苗建青,等. 血清细胞因子水平与患者肝硬化腹水感染的相关性研究. 中华医院感染学杂志,2018,28(14):2101-2104. [17] Tian CH, Dai J, Zhang W,et al. Expression of IL-17 and its gene promoter methylation status are associated with the progression of chronic hepatitis B virus infection. Medicine (Baltimore), 2019,98(23):15924. [18] Losada B, Guerra JA, Malón D,et al. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. Clin Transl Oncol, 2019,21(7):855-863. [19] Hong H, Fang X, Huang H,et al. The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol, 2020,189(5):908-912. [20] Liu XY, He X, Cai M,et al. Prognostic value of complete blood cell count-derived inflammatory markers in hepatitis B virus-related acute-on-chronic liver failure. Clin Lab, 2021,67(10):11-18. [21] Gatechompol S, Sophonphan J, Kerr SJ,et al. Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV. Int J Tuberc Lung Dis, 2021,25(11):933-938. [22] Cao F, Wan Y, Lei C,et al. Monocyte-to-lymphocyte ratio as a predictor of stroke-associated pneumonia: A retrospective study-based investigation. Brain Behav, 2021,11(6):2141. [23] Zhang F, Hu KS, Lu SX,et al. Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma. Cancer Biomark, 2021,31(3):211-225. [24] 范玥,李欣,周晓芳,等. 中性粒细胞淋巴细胞比值在预测乙型肝炎相关肝衰竭中的作用. 中华肝脏病杂志,2017,25(10):726-731. [25] Yuan X, Duan SZ, Cao J,et al. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol, 2019,31(11):1467-1474. [26] 牛兴杰,刘志慧,崔凤梅,等. 相关炎症指标预测慢性乙型肝炎患者肝纤维化程度的价值. 中华医院感染学杂志,2020,30(5):703-708. |